Lithium's antidepressant action may be mediated by inhibition of inositol monophosphatase (IMPase), a key enzyme in G qprotein coupled receptor signalling. Recently, the antioxidant agent ebselen was identified as an IMPase inhibitor. Here, we investigated both ebselen and lithium in models of the 5-HT 2A receptor, a G q -protein coupled receptor involved in lithium's actions. 
Introduction
Lithium is an important therapeutic agent in the prophylactic treatment of bipolar depression and suicide prevention and is valuable as an augmentation agent in treatmentresistant unipolar depression (Cipriani et al., 2005; Fountoulakis et al., 2012; Geddes and Miklowitz, 2013) . However, the full therapeutic potential of lithium is limited by poor tolerance and low treatment compliance due to adverse effects or symptoms of toxicity, as well as the requirement for careful monitoring of plasma levels.
Although there are several competing hypotheses regarding the molecular mechanism of lithium including inhibition of glycogen synthase kinase (GSK) 3 (Gould and Manji, 2005) , the 'inositol depletion' hypothesis is arguably one of the most favoured and long-standing (Berridge et al., 1989; Malhi et al., 2013) . This hypothesis posits that lithium attenuates transmitter-evoked, G q -protein coupled signalling via the phosphoinositide (PI) pathway through inhibition of inositol mono-phosphatase (IMPase). IMPase hydrolyses inositol monophosphate to inositol, and IMPase inhibition causes a depletion of inositol and thereby reduces the recycling of phospholipids that is required for PI signalling. Several lines of evidence associate IMPase inhibition with the therapeutic effects of lithium. For instance, higher levels of brain inositol are reported in bipolar disorder patients, and lithium reduces brain inositol levels in both patients and animals (Allison and Stewart, 1971; Davanzo et al., 2001) . Also, IMPase knockout mice (specifically mice lacking IMPA1 that encodes the IMPase gene that regulates inositol metabolism in brain) show lithium-like effects in behavioural models (Cryns et al., 2008; Ohnishi et al., 2014) .
Another important link between IMPase and the antidepressant effects of lithium is the inhibition of signalling by the 5-HT 2A receptor, which is one of a family of G q -protein coupled 5-HT receptors (5-HT 2A , 5-HT 2B and 5-HT 2C ). Reduced 5-HT 2A receptor function is a common effect of many antidepressant drug treatments (see Celada et al., 2004; Quesseveur et al., 2012) , and 5-HT 2A receptor antagonists have a variety of relevant lithium-like neuropharmacological effects including reduced impulsivity (Winstanley et al., 2004) , as well as an antidepressantaugmenting action in various experimental models (Marek et al., 2003; Boothman et al., 2006) . Evidence that lithium reduces 5-HT 2A receptor function comes from findings that lithium causes (i) a 5-HT-evoked accumulation of inositol phosphates in cell and brain tissue preparations (Godfrey et al., 1989; Briddon et al., 1998; Rabin et al., 2002; Kurrasch-Orbaugh et al., 2003) , (ii) reduces 5-HT 2 receptor agonist induced head-twitches in rodents (Goodwin et al., 1986; Hotta et al., 1986) and (iii) enhances the increase in brain extracellular 5-HT, induced by inhibition of 5-HT uptake with selective serotonin re-uptake inhibitors (SSRI) (Muraki et al., 2001; Wegener et al., 2003; Kitaichi et al., 2005) , as seen with selective 5-HT 2A receptor antagonists (Gobert et al., 2000; Cremers et al., 2004; Boothman et al., 2006) . However, in another model of 5-HT 2A receptor function, agonist-evoked expression of the immediate early gene (IEG) c-fos (Scruggs et al., 2000; Pei et al., 2004; Gonzalez-Maeso et al., 2007) , lithium treatment was facilitatory not inhibitory (Leslie et al., 1993; Moorman and Leslie, 1998) .
Evidence linking IMPase to the therapeutic effects of lithium has triggered attempts to develop IMPase inhibitors. In one of few examples, Atack and colleagues (Atack, 1997) identified a potent IMPase inhibitor (L690330) and a structurally related prodrug (L690,488). Both agents were poorly bioavailable, although recent in vivo studies found lithium-like effects of high systemic doses of L690330 in mice (Atack et al., 1993; Shtein et al., 2013) . Other than this advance, progress in the development of IMPase inhibitors has been limited (Miller and Allemann, 2007) . In a recent drug-repurposing study, we identified the antioxidant agent ebselen as a brainpenetrant IMPase inhibitor (Singh et al., 2013) . Moreover, we reported preliminary evidence that ebselen reduced 5-HT 2A receptor function in the head-twitch and c-fos models (Singh et al., 2013) . Here, we further explored the effect of ebselen in these models and also tested the effect of lithium. We also investigated the antidepressant-augmenting potential of ebselen by examining its effect, alone and in combination with an SSRI, on extracellular 5-HT in brain.
Methods

Animals
All animal care and experimental procedures conformed to the UK Animals (Scientific Procedures) Act 1986 and were approved by the local ethical review process and covered by a Home Office Project Licence. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Male C57BL/6 mice (7-9 weeks; Harlan, Bicester, UK) were group-housed under controlled conditions of lighting (12 h light-dark cycle, lights on 08.00 h) and temperature (21 ± 1°C), with food and water freely available. Experiments were carried out during the light phase.
Behavioural measurements
Central 5-HT 2A receptor function was assessed in behavioural studies by measuring involuntary head-twitches (headtwitch response, HTR) evoked by administration of a hallucinogenic non-selective 5-HT 2A receptor agonist, DOI or psilocin. Stereotypical scratching of the ear (ear-scratch response, ESR) with one or two paws was also measured as this is another 5-HT 2A receptor-mediated effect of such agents (Darmani et al., 1990; Gonzalez-Maeso et al., 2007) . The challenge doses of DOI (2 mg·kg À1 i.p.) and psilocin (2 mg·kg À1 i.p.) were selected on the basis of our earlier dose response studies and our evidence that the DOI-induced HTR was blocked by a selective 5-HT 2A receptor antagonist (Jennings et al., 2008) . Groups of mice (group size as specified in Tables and  Figures) were randomly allocated to one of the following treatments (see Table 1 Table 1 for summary) were selected according to optimal times reported in previous studies; ebselen (1 h; Singh et al., 2013) , lithium (5 or 18 h; Goodwin et al., 1986) , L-690330 (1 h; Atack et al., 1993) and AR-A014418 (30 min; Gould et al., 2004) . Mice were placed individually in transparent, plexiglass chambers 1 h before administration of DOI (2 mg·kg À1 i.p.) or psilocin (2 mg·kg À1 i.p.). Behaviour was monitored by an overhead video camera, and the number of head-twitches and ear scratches was scored (5 min after agonist injection, for 15 min) offline by an observer blind to treatment. In many cases, data were analysed by a second (blinded) treatment observer, and the outcome was confirmed.
Measurement of IEG expression
In separate molecular studies, central 5-HT 2A receptor function was assessed by measuring DOI-induced mRNA expression of the IEG c-fos, as well as complementary IEGs Arc and Egr2 in cortical regions (Gonzalez-Maeso et al., 2007; Jennings et al., 2008) . The challenge dose of DOI (2 mg·kg À1 i.p.) was selected on the basis of preliminary dose response studies and evidence that DOI-evoked IEG expression was abolished by pretreatment with the selective 5-HT 2A receptor antagonist MDL 100907 (Jennings et al., 2008) . Groups of mice were acclimatized to a procedure room for 4 h prior to each experiment. Mice were randomly allocated to one of the following treatments; (i) acute ebselen (10 mg·kg À1 i.p.) or vehicle and (ii) repeated lithium (3 days; 10 mmol·kg À1 i.p. on day 1, 3 mmol·kg À1 i.p. twice daily on days 2-3) or vehicle. The last injection of drug prior to administration of DOI (2 mg·kg À1 i.p.) was 1 h for ebselen and 18 h for lithium. Drug doses and pretreatment times are summarized in Table 1 . One hour following administration of DOI, mice were killed by cervical dislocation, and brains were dissected, snap frozen in isopentane on dry ice and stored in À80°C. c-fos, Arc and Egr2 mRNA were measured on tissue sections using in situ hybridization (Jennings et al., 2008) . Coronal sections (12 μm) were cryostat-cut and collected on gelatinized slides. Sections were stored in À80°C prior to pretreatment with paraformaldehyde-based and triethanolamine/acetic acid-based solutions and dehydration with increasing concentrations of alcohol solutions. Slides were then allowed to air-dry overnight and stored in À20°C.
Oligonucleotide probes complementary to c-fos (CTTCAG GGTAGGTGAAGACAAAGG-AAGACGTGTAAGTAGTGCAGC), Arc (CTCGGTTGCCCATCCTCACCTGGCCCCCAAG-ACTGAT ATTGCTGA) and Egr2 (GGATCATAGGAATGAGACCTGGGT CCATAGCTGG-CTTGG) mRNA were 3 0 -tail labelled with [
35 S]-ATP (Hartmann Analytic GmbH, Braunschweig, Germany). For hybridization, sections were defrosted, cover-slipped and incubated at 34°C for 16 h with a hybridization mix (consisting of the radiolabelled oligonucleotide (2.4 × 10 6 cpm per section), 50 mM DTT and hybridization buffer (50% deionized formamide, 4× saline sodium citrate (SSC), 25 mM sodium phosphate buffer, 1 mM sodium pyrophosphate, 5× Denhart's solution, 0.2 μg·mL À1 boiled herring sperm, 0.1 mg·mL À1 polyadenylic acid, 120 μg·mL À1 heparin, 0.1 g·mL À1 dextran powder). Cover slips were then removed, and sections were washed with 1× SSC, 50°C for 20 min. Washes were repeated twice followed by 2× 60 min washes at room temperature with 1× SSC. Sections were then immersed in double deionized water and dried overnight before being placed in cassettes and exposed to autoradiographic film (Kodak BioMax MR) for 7 days. Autoradiographic films were developed using an automatic X-ray film processor (Compact X4, X-ograph, Wokingham, UK). Controls included using the sense orientation of the oligonucleotide and displacement with unlabelled probes. Optical density (OD) measurements were obtained from the autoradiograms using computer-based image analysis (MCID software, St. Catharines, ON, Canada). OD readings were converted in nCi·g À1 of tissue by calibration with the use of [ 14 C] microscales, which were co-exposed with the slides. Measurements of regions of interest were taken bilaterally from three sections per slide, and the values for each region of interest were averaged. (Pazos et al., 1984; Hoyer et al., 1985; Pazos et al., 1985) . The receptor autoradiography protocol was based on that of Pazos et al. (1985) .
Drug treatment paradigms followed those of the behavioural and IEG experiments. Thus, mice were randomly allocated to one of the following treatments; (i) acute ebselen (10 mg·kg À1 i.p.)
or vehicle, (ii) repeated ebselen (10 mg·kg À1 i.p., twice daily for 7 days; last injection morning of the eight day) or vehicle and (iii) repeated lithium (7 days; 10 mmol·kg À1 i.p. on day 1, 3 mmol·kg À1 i.p. twice daily on days 2-7) or vehicle.
Tissue sections (12 μm) were cryostat-cut at the level of the frontal cortex and stored in À80°C. On the day of the experiment, sections were incubated (at room temperature) in Tris-HCl buffer (0.17 M, pH 7.7) for 20 min and then for 2 h with either 2 nM [ 3 H]-ketanserin (PerkinElmer, Beaconsfield, UK) to determine total binding or 2 nM [ 3 H]-ketanserin plus 10 μM methysergide to determine non-specific binding. Sections were then washed twice for 10 min with ice-cold 4°C Tris-HCl buffer (0.17 M, pH 7.7), followed by double deionized water. Finally, slides were air-dried overnight before being exposed to autoradiographic films (BioMax MR, Sigma-Aldrich, Gillingham, UK) for 12 weeks. OD measurements were obtained from the autoradiograms as described above. Measurements were taken bilaterally, from three sections per slide, and values were averaged. Specific binding was calculated by subtracting non-specific binding from total binding. OD measurements were calibrated using 3 H-microscales that were co-exposed with the sections and converted to values of nCi·g À1 tissue.
Microdialysis
Mice were stably anaesthetized with isoflurane (2%, delivered in oxygen), and body temperature was maintained at 36 ± 1°C using a homeothermic blanket attached to a rectal probe. After mounting in a stereotaxic frame (Kopf, Tjunga, USA), a hole was drilled over the hippocampus, and a guide cannula (5 mm length, 0.2 mm outer diameter; Royem Scientific Ltd, Luton, UK) was stereotaxically lowered into the hippocampus (coordinates from bregma: AP À3.0, ML À3.3, DV À4.4; Franklin and Paxinos, 2008) and secured with dental cement. Mice were then removed from the frame and allowed to recover for 6-7 days. On the day of the experiment, mice were briefly anaesthetized with isoflurane, and a microdialysis probe (7 mm length, 2 mm 6 KDa PES membrane; Royem Scientific Ltd) was slowly lowered through the guide cannula, into the hippocampus. The microdialysis probe was connected to a perfusion pump (CMA/100, CMA Microdialysis Ltd., Stockholm, Sweden) and perfused (2 μL·min À1 ) continuously with artificial CSF (140 mM NaCl, 3 mM KCl, 1.2 mM Na 2 HPO 4 , 0.27 mM NaH 2 PO 4 , 1 mM MgCl 2 , 2.4 mM CaCl 2 and 7.2 mM glucose). After 2 h perfusate, samples were collected every 20 min and analysed immediately by HPLC with electrochemical detection (see below).
Once three consecutive baseline samples were stable, mice received a single injection of ebselen (10 On the day of neurochemical analysis, tissue pieces (~20 mg) of frozen frontal cortex and hippocampus were placed in Eppendorf tubes containing 500 μL perchloric acid (0.09 M) and homogenized using a Polytron kinetic homogenizer (15 000 rpm for 10 s). Tissue homogenates were then centrifuged (1000 × g for 10 min), and the supernatant was transferred in a new Eppendorf tube, protected from light and kept on ice before analysis using HPLC with electrochemical detection (see below).
HPLC with electrochemical detection
Both microdialysates (20 μL) and brain tissue supernatants (50 μL) were analysed by an HPLC system, comprising a silica-based, reversed phase column (3.0 μm ODS2, 4.6 mm × 100 mm, Waters Ltd, Borehamwood, UK) coupled to an electrochemical detector (glass carbon working electrode vs. Ag/AgCl reference; LC-4C, Bioanalytical systems, West Lafayette, USA). For microdialysates, analytes were separated at room temperature by an isocratic mobile phase comprising 12.5% (v/v) methanol, 0.13 M NaHPO 4 , 0.025 mM octane sulphonic acid, 0.85 mM EDTA and 2 mM NaCl at pH 3.5, and with the working electrode set at +0.7 V.
For measurement of 5-HT and 5-HIAA in brain tissue supernatants, analytes were separated at room temperature by an isocratic mobile phase comprising an isocratic mix of 15% (v/v) methanol, 2 mM 1-octanesulphonic acid, 0.12 M NaHPO 4 , 2 mM NaCl and 0.1 mM EDTA at pH 3.7 with the working electrode set at +0.85 V. For measurement of 5-HTP, the mobile phase was adjusted to pH 3.4.
Materials
Compounds used in this study were supplied as follows; 
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/2018 (Alexander et al., 2017a,b,c) Results
Effect of ebselen on DOI-evoked behavioural responses
Administration of the 5-HT 2A receptor agonist DOI (2 mg·kg À1 i.p.) evoked both a HTR and ESR ( Figure 1A ). i.p.) induced a HTR but not an ESR, as reported previously (Glennon, 2008) . The psilocin-induced HTR was also decreased by ebselen ( Figure 1B) . In mice treated repeatedly with vehicle (7 days), DOI evoked both a HTR and ESR. These responses to DOI were reduced in mice by similar treatment (10 mg·kg À1 i.p. for 7 days) with ebselen ( Figure 1C ).
Effect of lithium on DOI-evoked behavioural responses
The effect of lithium on the HTR and ESR to DOI was tested. Acute administration of lithium (10 mmol·kg À1 i.p.) reduced the ESR to DOI but the HTR was not significantly changed compared to vehicle controls ( Figure 2A ). However, repeated administration of lithium for 3 days (10 mmol·kg À1 i.p. day 1, 3 mmol·kg À1 i.p. days 2-3) decreased both the DOI-induced HTR and the ESR ( Figure 2B ). When administered repeatedly for 7 days (10 mmol·kg À1 i.p. day 1,
Figure 1
Effect of ebselen (Ebs) on 5-HT 2A receptor-mediated behavioural responses in the mouse. (A) DOI (2 mg·kg À1 ) plus ebselen administered acutely (1, 5 or 10 mg·kg À1 ). (B) Psilocin (Psil) (2 mg·kg À1 ) plus ebselen administered acutely (10 mg·kg À1 ). (C) DOI (2 mg·kg À1 ) plus ebselen administered repeatedly (10 mg·kg À1 , twice daily, for 7 days). Data shown are means ± SEM (n in brackets). *P < 0.05, significantly different from DOI or psilocin alone; one-way ANOVA followed by post hoc Sidak's test (see Supporting Information Data S1 for details). HTR, head-twitch response; ESR, ear-scratch response.
3 mmol·kg À1 i.p. days 2-7), lithium was similarly effective in reducing the DOI-evoked HTR and ESR, compared with vehicle controls ( Figure 2C ).
Effect of inhibitors of IMPase or GSK-3 on DOIevoked behavioural responses
To test whether IMPase inhibition might be involved in the inhibitory effect of ebselen and lithium on the behavioural measures of 5-HT 2A receptor function, the IMPase inhibitor, L-690330 was tested. Pretreatment with L-690330 (150 or 240 mg·kg À1 i.p.) decreased the DOI-induced-HTR, with a trend effect on the ESR ( Figure 3A) . Inhibition of GSK-3 is also a potential mediator of the actions of ebselen and lithium. However, pretreatment with the GSK-3 inhibitor AR-A014418 (10 or 20 mg·kg À1 i.p.) did not affect the DOIinduced HTR or ESR ( Figure 3B ).
Effect of ebselen on DOI-evoked IEG responses
Experiments tested whether the effect of ebselen on the behavioural measurement of 5-HT 2A receptor function could be confirmed by molecular measurement of 5-HT 2A receptor function using IEG expression. Compared to vehicle controls, DOI (2 mg·kg À1 i.p.) induced a marked increase in mRNA abundance of the IEGs c-fos, Arc and Egr2, and this effect was apparent across various brain regions. DOI evoked increases in IEG mRNA of approximately 50-200% above vehicle-injected controls (Figure 4 A-C). Statistical analysis revealed that DOI increased Arc mRNA in cingulate and somatosensory cortices. Similar findings were obtained for c-fos mRNA in the cingulate and somatosensory cortices, and Egr2 mRNA in the caudate nucleus and in the endopiriform cortex. Pretreatment with ebselen (10 mg·kg À1 i.p.) attenuated these IEG responses to DOI. This effect of ebselen was statistically significant for Arc in cingulate cortex ( Figure 4A ), for c-fos in cingulate and somatosensory cortices ( Figure 4B ), and for Egr2 in the caudate nucleus and endopiriform cortex ( Figure 4C ).
Effect of lithium on DOI-evoked IEG responses
Experiments also tested whether lithium reduced 5-HT 2A receptor function in the IEG mRNA expression model. In these on days 2-3). (C) DOI (2 mg·kg -1 ) plus lithium administered repeatedly for 7 days (10 mmol·kg À1 on day 1, 3 mmol·kg À1 , twice daily, on days 2-7). Data shown are means ± SEM (n in brackets). *P < 0.05, significantly different from DOI alone; one-way ANOVA followed by post hoc Sidak's test or Student's unpaired t-test as appropriate (see Supporting Information Data S1 for details). Abbreviations as in Figure 1 legend. these IEG responses to DOI. This effect of lithium was statistically significant for Arc in cingulate and somatosensory cortices ( Figure 5A ), for c-fos in cingulate and somatosensory cortices ( Figure 5B ), and for Egr2 in the caudate nucleus ( Figure 5C 
Figure 3
Effect of ebselen in combination with an SSRI on brain extracellular 5-HT
Previous microdialysis studies demonstrate that the increase in hippocampal extracellular 5-HT in response to administration of an SSRI is greater in animals treated with a 5-HT 2A receptor antagonist (Boothman et al., 2006) . Microdialysis experiments tested whether acute administration of ebselen would similarly enhance the effect of an SSRI. In awake mice, the SSRI citalopram (5 mg·kg À1 i.p.) increased levels of 5-HT in hippocampal microdialysates, an effect that peaked at approximately 450% above pre-drug values 60 min post injection ( Figure 6 ). Citalopram in combination with ebselen (10 mg·kg À1 ) also increased microdialysate levels of 5-HT. Notably, the effect of citalopram was greater when administered with ebselen (10 mg·kg À1 i.p.) than alone, with the greatest effect being 20-40 min post injection of citalopram ( Figure 6 ). In separate experiments, neither ebselen nor vehicle alone altered extracellular 5-HT.
Effect of ebselen on 5-HTsynthesis and tissue levels of 5-HTand 5-HIAA
Given the SSRI-augmenting effect of ebselen detected in the experiments described above, a final series of experiments tested the effect of different doses of ebselen (0.5, 1 and 5 mg·kg À1 ) on various ex vivo neurochemical measures of presynaptic 5-HT function (Table 3 ). In the model of 5-HT synthesis, ebselen increased 5-HTP levels in cortex and hippocampus, compared with vehicle controls. This increase in 5-HTP was apparent at the highest dose tested (5 mg·kg À1 ), but not at lower doses.
In separate experiments, ebselen increased the tissue levels of 5-HT in both cortex and hippocampus, compared with vehicle-injected controls, and this effect was observed at all doses tested (0.5, 1 and 5 mg·kg À1 ; Table 3 ). In comparison, 5-HIAA levels in the cortex and hippocampus of these ebselen-treated mice were not significantly different from vehicle controls. (6) Ebselen (2 h) 3.36 ± 0.38 (6) Ebselen (7 days) 6.12 ± 0.63 (6) Lithium (7 days) 5.43 ± 1.30 (6) Data shown are mean ± SEM (n) values. (Wegener et al., 2003; Boothman et al., 2006) . The latter effect of ebselen was associated with other neurochemical evidence that the drug increased 5-HT formation, as also demonstrated for lithium in earlier work (e.g. Knapp and Mandell, 1973) . Overall, these data suggest that ebselen has lithium-like effects on 5-HT 2A receptor function, including SSRI augmentation. DOI, the principal agonist used in the models of 5-HT 2A receptor function, is not selective for 5-HT 2A receptors versus other 5-HT 2 receptor subtypes, but an abundance of evidence demonstrates that the HTR/ESR and cortical IEG expression evoked by the drug are 5-HT 2A receptor-mediated. For example, in 5-HT 2A receptor knockout mice the HTR to DOI is abolished but then restored on conditional rescue (Gonzalez-Maeso et al., 2007) . Experiments using 5-HT 2A receptor knockout mice also show that the DOI-evoked increase in IEG expression in mouse somatosensory cortex and other cortical regions is 5-HT 2A receptor-dependent (Gonzalez-Maeso et al., 2003 . These data are supported by pharmacological experiments showing that the HTR and cortical IEG responses to DOI are blocked by selective 5-HT 2A receptor antagonists (Pei et al., 2004; Jennings et al., 2008) .
In the current study, acute ebselen attenuated DOIinduced behavioural responses in mice, and this effect persisted with repeated administration. Acute ebselen also reduced the HTR induced by another hallucinogenic 5-HT 2A receptor agonist, psilocin. Repeated lithium attenuated the HTR and ESR to DOI, although acute administration of lithium was less effective. The latter finding agrees with earlier reports that repeated (3 and 14 days) but not acute lithium treatment attenuated the HTR to the 5-HT precursor, 5-hydroxytryptophan, in mice and rats (Goodwin et al., 1986; Hotta et al., 1986) . The inhibitory actions of ebselen and lithium in the behavioural model of 5-HT 2A receptor function were supported by data from the IEG model. Thus, we found that both ebselen (acute) and lithium (3 days treatment) reduced the DOI-evoked increase in mRNA expression of three IEGs, c-fos, Arc and Egr2 in cortical regions. That lithium needed to be administered repeatedly to see robust effects on 5-HT 2A receptor function might reflect the dosing or timing of the acute treatment, although we cannot rule out some sort of adaptive mechanism.
Notwithstanding the latter point, although both ebselen and lithium have several pharmacological targets, the finding that both agents reduced 5-HT 2A receptor function in the behavioural and molecular models argues for a common mechanism of action, and IMPase inhibition is shared by both agents (Berridge et al., 1989; Singh et al., 2013) . Evidence in favour of a role for IMPase inhibition is the current finding that the IMPase inhibitor L-690330, at high systemic doses previously shown to inhibit central IMPase in vivo (Atack et al., 1993) , also decreased the HTR and ESR to DOI. Although inhibition of GSK-3 may contribute to lithium's psychotropic effects, ebselen is weakly active at this enzyme (Singh et al., 2013) . Moreover, the selective GSK-3 inhibitor AR-A 014418 did not attentuate the behavioural response to DOI at doses shown previously to enter the brain in concentrations sufficient to inhibit GSK-3 (Gould et al., 2004; Kalinichev and Dawson, 2011) . Thus, the effects of ebselen and lithium in the models of 5-HT 2A receptor function are consistent with the idea that these agents act indirectly by inhibiting IMPase to disrupt 5-HT 2A receptor activated PI signalling that is required to elicit the downstream behavioural and molecular responses.
Further evidence supporting a role for IMPase inhibition and PI signalling in the effects of ebselen and lithium is the earlier finding that the increase in IEG expression induced by 5-HT 2A agonist administration was blocked by a phospholipase C inhibitor (Gonzalez-Maeso et al., 2007) . Similarly, local administration of a phospholipase C inhibitor into the mPFC abolished the DOI-induced HTR in rabbits (Schindler et al., 2013) . Indeed, IMPase inhibition in the frontal cortex may be central to the actions of ebselen and lithium because both the molecular and behavioural responses to 5-HT 2A receptor activation are likely to derive from a direct (Goodwin et al., 1986) . Unlike genetic knockout or pharmacological antagonism of the 5-HT 2A receptor, neither ebselen nor lithium completely blocked the behavioural and molecular responses to DOI. This might be explained in part by incomplete inhibition of IMPase at the doses used. Although ebselen inhibited IMPase ex vivo in the same dose that was used in the present study (10 mg·kg À1 ), that inhibition was not total (Singh et al., 2013) . Moreover, neither ebselen nor lithium completely depleted inositol levels in the doses administered in the present study (Allison and Stewart, 1971; Singh et al., 2013) , possibly indicating incomplete IMPase inhibition. However, due to poor solubility (ebselen) or toxicity (lithium), it was not possible to investigate the effect of higher doses of these agents. Our data do not exclude a role for other mechanisms in the effects of ebselen or lithium. For instance, it is well known that 5-HT 2A receptors are under the negative influence of mGlu 2 receptors (González-Maeso et al., 2008). However, we are not aware of any evidence that ebselen or lithium interact with mGlu 2 receptors. It should also be noted that the current finding that lithium reduced 5-HT 2A receptor function in the IEG model conflicts with earlier reports that lithium enhanced the effects of DOI on fos expression (Leslie et al., 1993; Moorman and Leslie, 1998) . The latter studies used rats and measured fos protein rather than mRNA. Perhaps more importantly, the latter studies used a high dose of DOI (8 mg·kg À1 ), and toxic behavioural effects were noted (convulsions) that may have confounded interpretation of the data. Moreover, these earlier results with lithium are at odds with findings that lithium consistently reduces 5-HT 2A receptor function in the behavioural models (present study; Goodwin et al., 1986; Hotta et al., 1986) and the current findings that ebselen also reduced 5-HT 2A receptor function. Both lithium and 5-HT 2A receptor antagonists are reported to augment neuropharmacological effects of SSRIs in preclinical models (Wegener et al., 2003; Boothman et al., 2006) , and SSRI augmentation is an important therapeutic use of lithium and drugs with 5-HT 2A receptor antagonist properties in treatment-resistant depression (see Marek et al., 2003) . It is interesting therefore that, in the current microdialysis experiments, ebselen, at a dose that reduced 5-HT 2A receptor function, augmented the increase in extracellular 5-HT (in hippocampus) induced by the SSRI citalopram. Similar findings have been previously reported for both lithium and selective 5-HT 2A receptor antagonists (Wegener et al., 2003; Boothman et al., 2006) . Given that certain 5-HT 2A receptor populations are involved in 5-HT feedback control (Sharp et al., 2007) , reduced 5-HT 2A receptor function may account for ebselen's SSRI augmenting effect. In this regard, an additional or alternative mechanism of action of ebselen is increased presynaptic 5-HT function as evident from the current findings that the drug elevated cortical and hippocampal tissue 5-HT levels and also increased 5-HT synthesis, albeit at higher doses. The latter effects of ebselen are reminiscent of similar findings with lithium in earlier studies (e.g. Knapp and Mandell, 1973) .
As a final point, the current HTR, ESR and IEG data were generally complementary in terms of the effects of ebselen and lithium and are assumed to be functional readouts of a similar pharmacological mechanism, that is, 5-HT 2A receptor mediated responses due to activation of the PI pathway. It is now recognized that 5-HT 2A receptor signalling goes beyond activation of the canonical PI pathway. For instance, noncanonical signalling pathways associated with 5-HT 2A receptor activation include PLA 2 , the ERK pathway and signalling via small G proteins such as Rho A (see Halberstadt, 2015; McCorvy and Roth, 2015) . Although the precise functions mediated by the canonical and non-canonical signalling pathways have not yet been identified conclusively, it is noteworthy that 5-HT 2A receptors have multiple and profound effects in the CNS as well as periphery (vascular and other smooth muscle). Thus, a selective reduction in canonical versus non-canonical 5-HT 2A receptor signalling might bring functional differences and potential therapeutic advantages.
In summary, the current data demonstrate that ebselen, like lithium, decreased 5-HT 2A receptor function in behavioural and molecular models and provide evidence that IMPase inhibition may be involved. Other lithium-like effects of ebselen are reported in both animals and humans (Singh et al., 2013; Masaki et al., 2016; Singh et al., 2016) . Moreover, ebselen has been found to be safe and tolerated in humans (see Masaki et al., 2016; Singh et al., 2016) . Ebselen may therefore have utility in the management of conditions that respond to lithium such as bipolar depression, impulsivity and treatment-resistant depression (Singh et al., 2013; Masaki et al., 2016) .
between the University and other collaborating institutions. The other authors declare no conflicts of interest.
Declaration of transparency and scientific rigour
